Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
116 results about "Mutant cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A mutant cell line is produced in which a motor protein specific for astral microtubules is inactivated.
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the genome of the cells. The nature of the Library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the Library. The invention includes the described Library, methods of making the same, and vectors used to construct the Library. Methods are also provided for accessing individual parts of the Library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the Library.
Owner:LEXICON PHARM INC
Vectors for gene mutagenesis and gene discovery
InactiveUS6436707B1Quick identificationLimit exploitationBiocideGenetic material ingredientsGene mutationGene trapping
Novel vectors are described that incorporate, inter alia, a novel 3' gene trap cassette which can be used to efficiently trap and identify previously unknown cellular genes. Vectors incorporating the described 3' gene trap cassette find particular application in gene discovery and in the production of mutated cells and animals.
Owner:LEXICON PHARM INC
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the genome of the cells. The nature of the Library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the Library. The invention includes the described Library, methods of making the same, and vectors used to construct the Library. Methods are also provided for accessing individual parts of the Library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the Library.
Owner:LEXICON PHARM INC
Modified cytokine
InactiveUS7112660B1Increase intrinsic stabilityIncrease of to proteolytic degradationPeptide/protein ingredientsPeptide preparation methodsProtein secondary structureSolvent
The invention relates to methods for the stabilisation of cytokines and to cytokines generated by such methods. The methods of the invention involve mutating the amino acid sequence of a cytokine so as to remove solvent-exposed hydrophobic residues, and / or mutating the amino acid sequence of the cytokine so as to stabilise one or more secondary structure elements in the molecule. These steps have the effect of destabilsing intermediates that are formed during the folding process, relative to the stability of the cytokine in its naturally folded state, so increasing the yield of the cytokine as produced in vitro.
Owner:BAYER SCHERING PHARMA AG +1
Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment
Owner:GENKIN DMITRY DMITRIEVICH +1
Cell-based systems for producing influenza vaccines
ActiveUS20100021499A1Minimize and prevent virus infectionAvoid componentsSsRNA viruses negative-senseAnimal cellsHemagglutininBinding site
The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines.
Owner:FLUGEN
Methods for producing heterologous polypeptides in trichothecene-deficient filamentous fungal mutant cells
Owner:NOVOZYMES INC
QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
InactiveUS7358057B2Less stringentEffective functionDrug screeningFermentationAcetylcholine receptorCell biology
The present invention relates e.g., to QM-7 or QT-6 cells comprising a heterologous mutant nicotinic α7 acetylcholine receptor and / or a nucleic acid encoding it, or a fragment or variant thereof. In a preferred embodiment, the mutant nicotinic α7 acetylcholine receptor subunit has a mutation in the M2 domain. QM-7 and QT-6 cells of the invention are useful for, e.g., assays such as high throughput assays that measure the influx of cations, such as Ca++ ions, into a cell. Such assays can be used, e.g., to identify agents that modulate the expression and / or activity of a mutant cell-surface-expressed channel receptor (e.g., the nicotinic α7 receptor), and which thus modulate, e.g., among other functions, processes involved in the central nervous system, such as learning and memory.
Owner:MEMORY PHARMA CORP
Novel murine polynucleotide sequences and mutant cells and mutant animals defined thereby
InactiveUS20020102543A1Sugar derivativesMicrobiological testing/measurementDiagnostic agentNovel gene
Novel murine polynucleotides are disclosed that individually identify novel genes into which a retroviral gene trap vector has integrated. Additionally, novel mutated murine ES cells are described that stably incorporate retroviral gene trap constructs into the specifically identified genes. The novel genes and cells thus defined are useful in functional genomic analysis, and in the discovery and development of new therapeutic and diagnostics agents and methods.
Owner:FRIEDRICH GLENN +2
Method for generating hypermutable organisms
InactiveUS20050188428A1Restore stabilityEnhance mutation rateMutant preparationTissue cultureGenetically modified animalOrganism
Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. The enhanced rate of mutation can be further augmented using mutagens. Moreover, the hypermutability of mismatch repair deficient cells can be remedied to stabilize cells or mammals with useful mutations.
Owner:EISAI INC
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the genome of the cells. The nature of the Library and the vectors allow for methods of screening for mutations in specific genes, and for gathering nucleotide sequence data from each mutated gene to provide a database of tagged gene sequences. Such a database provides a means to access the individual mutant cell clones contained in the Library. The invention includes the described Library, methods of making the same, and vectors used to construct the Library. Methods are also provided for accessing individual parts of the Library either by sequence or by pooling and screening. The invention also provides for the generation of non-human transgenic animals which are mutant for specific genes as isolated and generated from the cells of the Library.
Owner:LEXICON PHARM INC
Morphological mutants of filamentous fungi
InactiveUS7198938B2Restricted colonial phenotypeExtensive hyphal branchingFungiHydrolasesBiotechnologyHeterologous
The present invention relates to methods of obtaining a mutant cell from a filamentous fungal parent cell, comprising: (a) obtaining mutant cells of the parent cell; (b) identifying the mutant cell which exhibits a more restricted colonial phenotype and / or a more extensive hyphal branching than the parent cell; and (c) identifying the mutant cell which has an improved property for production of a heterologous polypeptide than the parent cell, when the mutant and parent cells are cultured under the same conditions.
Owner:NOVOZYMES INC
Low Fucose Cell Lines And Uses Thereof
A method of selecting cells having zero fucose level useful as host cells for expressing recombinant proteins is disclosed. The method comprises: (d) introducing genetic mutations into a population of CHO cells by contacting the cells with a methotrexate (MTX), (e) contacting the population of CHO cells comprising mutated cells with a non-toxic fucose binding agent for an amount of time that allows binding of the fucose binding agent to a fucose moiety on a cell membrane of the population of cells, wherein the amount of time does not allow killing of the cells; and (f) depleting from the population of cells comprising mutated cells, a subpopulation of cells which bind the fucose binding agent, thereby selecting cells useful as host cells for expressing recombinant proteins, the selected cells having zero fucose content. There are also disclosed cells and cell lines useful as host cells for expressing recombinant proteins.
Owner:MERCK SERONO SA
Application of nano copper powder in preparation of immunopotentiator medicine
InactiveCN1476843AImprove thymus indexIncrease spleen indexPowder deliveryInorganic active ingredientsDiseaseDead cell
The present invention relates the application of nano copper powder in preparation of immunity-enhancing medicine. It adopts the commercial nano copper powder whose grain size is 0.1-1000 nm as raw material, the weight ratio of raw material nano copper powder required for preparing medicine and preparation is 0.002-0.04:1. Said nano copper powder has the enhancement for specific immunity and non-specific immunity of body, and said medicine can be used for curing various diseases due to infective microbe and its toxin, tumor, dead cell or mutant cell.
Owner:马驷 +1
2-aminopyridine derivative containing 2-pyridone ring side chain, preparation and application
InactiveCN106083708AStrong growth inhibitory effectEnhanced inhibitory effectOrganic chemistryAntineoplastic agentsEnantiomerSide chain
The invention provides a 2-aminopyridine derivative containing a 2-pyridone ring side chain or an enantiomer of the 2-aminopyridine derivative. The target compound is obtained mainly by taking 2-aminopyridine as a parent nucleus to be coupled with a 4-bromo-2-pyridone ring. Experiments prove that the 2-aminopyridine derivative has a significant proliferation inhibition effect on tumor cells Karpas 299 (NPM-ALK positive cell lines) related to the ALK tyrosine kinase activity, NCI-H2228 (EML4-ALK positive cell lines), SKN-BE2 (ALK gene amplification cell lines) and SH-SY5Y (ALK F1174 mutant cell lines) and can be prepared into corresponding anti-tumor-cell drugs. The 2-aminopyridine derivative has a general structural formula I (please see the formula in the description).
Owner:ZHEJIANG UNIV
Mutant cells with enhanced resistance to desiccation
InactiveUS20050053991A1Improve the immunityImprove survivabilityMicrobiological testing/measurementMicroorganism preservationCompetent cellSurvivability
The invention provides a method of isolating desiccation resistant cells which retain good viability over long periods of time at room temperature for a variety of applications. In one embodiment, competent cells for DNA transformation are made from selected bacterial cells which are storage stable at room temperature.
Owner:GREENER ALAN +2
Application of nano copper powder in preparation of immunopotentiator medicine
InactiveCN1194668CImprove thymus indexIncrease spleen indexPowder deliveryInorganic active ingredientsDiseaseDead cell
Owner:马驷 +1
Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
InactiveUS20120015960A1Effectively treatingEffectively preventingBiocideOrganic chemistryBULK ACTIVE INGREDIENTLung cancer
Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and colon cancer, of which diagnosis or treatment is not easy.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1
Mutant cytokine fusion protein for treating metabolic diseases
ActiveCN106397569ALower blood sugar levelsHigh activityPeptide/protein ingredientsMetabolism disorderDiseaseMammal
The invention discloses the effect of a novel mutant human cytokine and fusion protein thereof on treatment of metabolic diseases. The human cytokine with mutant expression in mammalian cells is protein as shown in SEQ ID No. 3 in a sequence table. According to the invention, a wild human cytokine gene is subjected to mutation and N-terminal reconstruction, and the fusion protein contains a human cytokine mutant and the Fc segment (CH2-CH3) of human IgG4. The mammalian cell-expressed recombinant cytokine fusion protein has good activity in reducing blood sugar; in particular, the fusion protein has the advantages of high stability, long half life, etc.; and the fusion protein can well control fluctuation of blood sugar and stably maintain blood sugar at a normal level within 24 h.
Owner:哈尔滨资治生物科技有限公司
Method for knocking out AAV receptor, HEK293 cell strain with AAV receptor knocked out and application
ActiveCN107245475AReduce lossesIncrease final yieldCell receptors/surface-antigens/surface-determinantsVectorsCytologyCell strain
The invention relates to the field of gene engineering and cytology, in particular to an AAV receptor knocking out method, an HEK293 cell strain with an AAV receptor being knocked out and an application. The knocked-out AAV receptor is KIAA0319L. The knocking out method comprises the following steps: establishing a sgRNA carrier of a targeted AAVR genome sequence; carrying out transfection for a 293 T-cell, and culturing to obtain each clonal cell; carrying out Suveyor gene mutation analysis test; selecting AAVR mutant monoclone; then selecting an AAVR mutant cell strain with high yield of AAV; identifying a mutation condition of other potential mutant site; and enlarging the cell strain without other mutant sites, and establishing a library for production. The final yield of the AAV produced by the HEK293 cell strain of the knocked-out AAV receptor is about 50 percent higher than the yield of the conventional HEK293.
Owner:GUANGZHOU PACKGENE BIOTECH CO LTD
Vectors for gene mutagenesis and gene discovery
InactiveUS20020182724A1Quick identificationLimit exploitationMicroorganism based processesMicroorganism librariesGene trappingBioinformatics
Owner:LEXICON PHARM INC
Mutant cells for protein secretion and lignocellulose degradation
The present disclosure provides mutant cells for the secretion of proteins and for the degradation of lignocellulosic biomass. Methods for the use of these cells are also provided. Specifically, the utility of combined genetic deletions of β-glucosidases and the catabolite repressor gene creA / cre-1 for protein secretion in fungal and yeast cells is disclosed.
Owner:RGT UNIV OF CALIFORNIA
Preparation method of high-mutation urine stem cells in mitochondria mt.3243A > G mutation crowds
PendingCN111269883ASignificant technological progressCompound screeningCell dissociation methodsNew medicationsPrimary cell
The invention provides a preparation method of high-mutation urine stem cells in mitochondria mt.3243A > G mutation crowds. The method comprises the following steps: collecting urine cells of mitochondria mt.3243A > G mutant population; obtaining a sediment red tube by adopting a mode of centrifuging and adding a PBS to blow, beat and mix uniformly, obtaining P1-generation high-mutation urine stemcells are obtained, and obtaining the mitochondria mt.3243A > G mutation urine stem cells with the high mutation rate of 95% or above through digestion passage and mutation rate detection. The methodhas the advantages that the method can be obtained in a non-invasive mode, and the method can be obtained regardless of the gender, age and health condition of the patient. As a primary cell, the cell line maintains the basic properties of the original cell. The invention provides a cell application platform for researching the pathogenesis of mt.3243A > G mutant cells in the future and screeningnew drugs aiming at mt.3243A > G.
Owner:SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Novel mutated mammalian cells and animals
Novel mutated mammalian cells are provided that have been characterized by identifying the sequence of the genes that have been mutated. Preferably, novel mutated cells are murine ES cells that stably incorporate retroviral gene trap constructs in the specifically identified genes. The novel mutated cells and animals are useful in functional genomic analysis, and in the discovery and development of new therapeutic and diagnostics agents and methods.
Owner:FRIEDRICH GLENN +2
Inducible site-directed mutagenesis through conditional gene rescue
The present invention relates to a conditionally inducible site-directed mutant cell, comprising a mutated allele of a gene; wherein said allele comprises a mutation that was introduced by using a suitable mutagenesis technique, a rescue allele of said mutated gene that can be conditionally inactivated, wherein said mutation in said mutated allele of said gene interferes with survival and / or causes, an adverse phenotype, such as temporal and / or local phenotypes, such as cell cycle-specific, cell-type specific, tissue-specific, protein-expression specific, tissue-development specific, organ-specific, organ-development-specific and / or embryonic lethal phenotypes. According to further aspects thereof, the present invention relates to a conditionally inducible site-directed mutant cell culture, tissue, organ, or non-human embryo, comprising a cell and a respective non-human organism, in particular a genetically deficient or Knock-outmammal, -rodent, -nematode, -fish, -plant or -insect. Finally the invention provides a method for inducible site-directed mutagenesis through conditional gene rescue, either in vitro or in vivo.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative
ActiveCN111848631AHighly toxicEnhanced inhibitory effectOrganic active ingredientsOrganic chemistryTyrosine-kinase inhibitorTyrosine
The invention provides a pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound shown as a formula I, or a salt thereof, or a stereoisomer thereof. The compound disclosed by the invention is low in toxicity to normal cells, has an obvious inhibition effect on a lung cancer cell line, particularly has good selectivity on EGFR mutant cells HCC827, and has an obvious inhibition effect; meanwhile, the compound provided by the invention can effectively inhibit phosphorylation of EGFR. In addition, the compound provided by the invention has good inhibitory activity and selectivity on mutant EGFR. The compound disclosed by the invention can be used for treating lung cancer, particularly non-small cell lung cancer, has a relatively strong inhibition effect on EGFR mutant lung cancer, and is relatively low in toxicity; the compound can also be used for preparing tyrosine kinase inhibitors, especially EGFR phosphorylation inhibitors, and has good application prospects.
![Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative](https://images-eureka.patsnap.com/patent_img/2b00021a-28bf-42d2-9f8c-30f3ab145e3c/HDA0002656190280000011.png "Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative")
![Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative](https://images-eureka.patsnap.com/patent_img/2b00021a-28bf-42d2-9f8c-30f3ab145e3c/HDA0002656190280000012.png "Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative")
![Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative](https://images-eureka.patsnap.com/patent_img/2b00021a-28bf-42d2-9f8c-30f3ab145e3c/HDA0002656190280000021.png "Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative")
Owner:WEST CHINA HOSPITAL SICHUAN UNIV +1
Process for producing prenyl alcohols
InactiveUS20080213847A1Reduce the amount requiredPolypeptide with localisation/targeting motifFungiAlcoholFusion gene
Owner:TOYOTA JIDOSHA KK
Plant having mutant cyclin f-box gene
ActiveUS20190110420A1Easy to produceHigh in sugarMicrobiological testing/measurementClimate change adaptationAmino acid substitutionWild type
The present invention relates to a plant having an improved sugar content in fruit compared with its wild type plant, which has a mutant cyclin F-box gene comprising a nucleotide mutation that causes a non-conservative amino acid substitution in the cyclin F-box protein. The present invention also relates to a parthenocarpic plant having a mutant cyclin F-box gene comprising a nucleotide mutation that causes a non-conservative amino acid substitution in the cyclin F-box protein.
Owner:UNIV OF TSUKUBA
Method for screening biallelic mutant cell lines by Cas12a protein
InactiveCN110438161ASolve difficult-to-screen problemsEfficient screeningHydrolasesStable introduction of DNANucleic acid detectionCell biology
The invention relates to a method for screening biallelic mutant cell lines by Cas12a protein, is mainly used for screening biallelic mutant cell lines after CRISPR / Cas9 editing and solves the technical problem that biallelic mutant cell lines are difficult to screen out. A nucleic acid detection technology developed on the basis of Cas12a protein (including all bacterial sources) can screen biallelic mutant positive cells after CRISPR / Cas9 editing simply, efficiently and stably, and the method can partially replace a sequencing method and greatly reduces the screening cost.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN
In-vitro amplification method of iNKT cells
InactiveCN110872575AIncrease the amplification factorIncrease lethalityCulture processBlood/immune system cellsDendritic cellDendrite
Owner:中冠赛尔生物科技(北京)有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com